CLDX — Celldex Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $2.07bn
- $1.55bn
- $1.55m
Annual income statement for Celldex Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 4.65 | 2.36 | 6.88 | 7.02 | 1.54 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 75.9 | 118 | 161 | 202 | 289 |
| Operating Profit | -71.2 | -115 | -155 | -195 | -287 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -70.7 | -112 | -141 | -158 | -259 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -70.5 | -112 | -141 | -158 | -259 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -70.5 | -112 | -141 | -158 | -259 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -70.5 | -112 | -141 | -158 | -259 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.59 | -2.08 | -2.66 | -2.45 | -3.9 |